Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Long-Term Investments: 2018

  • Akebia Therapeutics' Long-Term Investments was N/A to $245,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $245,000, marking a year-over-year change of. This contributed to the annual value of $245,000 for FY2018, which is N/A change from last year.
  • Latest data reveals that Akebia Therapeutics reported Long-Term Investments of $245,000 as of Q4 2018.
  • Akebia Therapeutics' Long-Term Investments' 5-year high stood at $245,000 during Q4 2018, with a 5-year trough of $245,000 in Q4 2018.
  • Moreover, its 1-year median value for Long-Term Investments was $245,000 (2018), whereas its average is $245,000.